Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations: 2009-2025
Historic Income from Continuing Operations for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $432.0 million.
- Teva Pharmaceutical Industries' Income from Continuing Operations rose 209.92% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $658.0 million, marking a year-over-year increase of 125.84%. This contributed to the annual value of -$2.0 billion for FY2024, which is 217.67% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Income from Continuing Operations stood at $432.0 million for Q3 2025, which was up 53.74% from $281.0 million recorded in Q2 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Income from Continuing Operations registered a high of $519.0 million during Q1 2024, and its lowest value of -$1.8 billion during Q4 2023.
- For the 3-year period, Teva Pharmaceutical Industries' Income from Continuing Operations averaged around -$270.2 million, with its median value being -$253.0 million (2023).
- Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 1,286.59% in 2022, then skyrocketed by 305.14% in 2024.
- Teva Pharmaceutical Industries' Income from Continuing Operations (Quarterly) stood at -$151.0 million in 2021, then tumbled by 783.44% to -$1.3 billion in 2022, then crashed by 34.63% to -$1.8 billion in 2023, then surged by 84.69% to -$275.0 million in 2024, then soared by 209.92% to $432.0 million in 2025.
- Its Income from Continuing Operations was $432.0 million in Q3 2025, compared to $281.0 million in Q2 2025 and $220.0 million in Q1 2025.